Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 12/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429532 | 1.00 | CHRM3 (0.44) | CHRM3CHRM2CHRM1LMNACYP2C9 | |
| SCHEMBL5431021 | 0.98 | CHRM3 (0.45) | CHRM3CHRM2CHRM1LMNACYP2C9 | |
| SCHEMBL5110174 | 0.95 | CHRM3 (0.49) | CHRM3CHRM2CHRM1LMNACYP2C9 | |
| SCHEMBL5103094 | 0.93 | CHRM3 (0.50) | CHRM3CHRM2CHRM1LMNACYP2C9 | |
| SCHEMBL5439639 | 0.82 | CHRM3 (0.54) | CHRM3CHRM2CHRM1 | |
| SCHEMBL5439637 | 0.82 | CHRM3 (0.54) | CHRM3CHRM2CHRM1 | |
| SCHEMBL13559728 | 0.76 | CHRM3 (0.47) | CHRM3CHRM2CHRM1LMNACYP2C9 | |
| SCHEMBL8518913 | 0.73 | CYP1A2 (0.36) | CHRM2CHRM1CHRM4 | |
| SCHEMBL16616932 | 0.73 | CYP1A2 (0.36) | CHRM2CHRM1CHRM4 | |
| SCHEMBL4162513 | 0.73 | CHRM3 (0.51) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076061-A1 | MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1781103-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-05-14 | — | — | EP | disclosed |
| EP-1781103-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006017767-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076061-A1 | MUSCARINIC ACETYCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNA7, CHRNA2 | CHRM3 1/4885CHRM2 7/4885CHRM1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.